Vascular and structural alterations of the choroid evaluated by optical coherence tomography angiography and optical coherence tomography after half-fluence photodynamic therapy in chronic central serous chorioretinopathy
- 171 Downloads
To concurrently evaluate the effect of half-fluence photodynamic therapy (hf PDT) on choriocapillaris (CC) perfusion and choroidal structure in chronic central serous chorioretinopathy (CSC).
This prospective study included 48 eyes of 41 patients with chronic CSC. Enhanced depth imaging optical coherence tomography and optical coherence tomography angiography (OCTA) images were analyzed. Choroidal area (CA), luminal area (LA), and stromal area (SA) were computed using Image J software.
One month after hf-PDT, total CA decreased to 1.312 mm2 from 1.490 mm2 (p < 0.001), LA decreased to 0.981 mm2 from 1.097 mm2 (p < 0.001), and SA decreased to 0.331 mm2 from 0.393 mm2 (p < 0.001). In OCTA, the CC flow in the eyes with CSC (17.75 mm2) was statistically significantly lower than the fellow eyes (18.93 mm2) at the baseline visit (p < 0.001). After hf-PDT, the flow in the choriocapillaris statistically significantly increased to 18.81 mm2 at the first month (p = 0.02).
OCTA proves that after hf-PDT a significant increase in CC perfusion occurred at first month. The decrease of the luminal areas in enhanced depth imaging optical coherence tomography is mainly due to a decrease in large-caliber vessels, which indicates that hf-PDT has an effect on larger choroidal vessels and spares CC flow.
KeywordsHalf-fluence photodynamic therapy Optical coherence tomography angiography Chronic central serous chorioretinopathy Choriocapillaris perfusion
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 5.Rabiolo A, Zucchiatti I, Marchese A, Baldin G, Sacconi R, Montorio D, Cicinelli MV, Querques L, Bandello F, Querques G, Medscape (2018) Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy. Eye (Lond) 32:55–66. https://doi.org/10.1038/eye.2017.290 CrossRefGoogle Scholar
- 7.Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, Park TK, Moon SW, Chung H (2011) A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 152:784–792 e782. https://doi.org/10.1016/j.ajo.2011.04.008 CrossRefGoogle Scholar
- 10.Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P (2015) Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev CD011841. https://doi.org/10.1002/14651858.CD011841.pub2
- 11.Alkin Z, Perente I, Ozkaya A, Alp D, Agca A, Aygit ED, Korkmaz S, Yazici AT, Demirok A (2014) Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Clin Ophthalmol 8:685–690. https://doi.org/10.2147/OPTH.S58617.opth-8-685 CrossRefGoogle Scholar
- 15.Chan WM, Lai TY, Lai RY, Liu DT, Lam DS (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115:1756–1765. https://doi.org/10.1016/j.ophtha.2008.04.014.S0161-6420(08)00373-4 CrossRefGoogle Scholar
- 18.Taban M, Boyer DS, Thomas EL (2004) Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 137:1073–1080. https://doi.org/10.1016/j.ajo.2004.01.043.S000293940400087X CrossRefGoogle Scholar
- 19.Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, Sanfilippo M, Russo A, Uva MG, Munno F, Cannemi V, Zagari M, Boscia F (2010) Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 149:307–315 e302. https://doi.org/10.1016/j.ajo.2009.08.026 CrossRefGoogle Scholar
- 20.Schlotzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U (2002) Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 240:748–757. https://doi.org/10.1007/s00417-002-0517-4 CrossRefGoogle Scholar
- 21.Bonini Filho MA, de Carlo TE, Ferrara D, Adhi M, Baumal CR, Witkin AJ, Reichel E, Duker JS, Waheed NK (2015) Association of choroidal neovascularization and central serous chorioretinopathy with optical coherence tomography angiography. JAMA Ophthalmol 133:899–906. https://doi.org/10.1001/jamaophthalmol.2015.1320 CrossRefGoogle Scholar
- 24.Demirel S, Yanik O, Nalci H, Batioglu F, Ozmert E (2017) The use of optical coherence tomography angiography in pachychoroid spectrum diseases: a concurrent comparison with dye angiography. Graefes Arch Clin Exp Ophthalmol 255:2317–2324. https://doi.org/10.1007/s00417-017-3793-8 CrossRefGoogle Scholar
- 30.Demircan A, Yesilkaya C, Alkin Z (2018) Early choriocapillaris changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy evaluated by optical coherence tomography angiography: preliminary results. Photodiagn Photodyn Ther 21:375–378. https://doi.org/10.1016/j.pdpdt.2018.01.015 CrossRefGoogle Scholar
- 31.Nassisi M, Lavia C, Alovisi C, Musso L, Eandi CM (2017) Short-term choriocapillaris changes in patients with central serous chorioretinopathy after half-dose photodynamic therapy. Int J Mol Sci 18. https://doi.org/10.3390/ijms18112468